Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERACYTE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERACYTE's regulatory disclosures and financial reporting.
Veracyte reported a strong first quarter of 2026, returning solid growth and profitability. Total revenue rose to $139.1 million from $114.5 million a year earlier, driven mainly by a 26% increase in testing revenue to $135.1 million as diagnostic test volume grew 19% to 45,248.
Net income increased to $28.7 million from $7.0 million, with basic EPS rising to $0.36 from $0.09, helped by higher gross profit and lower general and administrative expense. Operating cash flow improved to $35.2 million, and cash, cash equivalents and short-term investments totaled $439.1 million, supporting ongoing investment in R&D and new cancer diagnostic offerings.
Veracyte reported strong first-quarter 2026 results with higher growth and profitability. Total revenue rose 21% to $139.1 million, led by testing revenue of $135.1 million, up 26%, driven by Decipher revenue of $86.5 million and Afirma revenue of $46.4 million.
Profitability improved significantly. GAAP net income was $28.7 million, or 20.6% of revenue, compared with $7.0 million a year earlier, and adjusted EBITDA reached $42.8 million, or 30.8% of revenue. Cash from operations was $35.2 million, and Veracyte ended March 31, 2026 with $439.1 million in cash, cash equivalents and short-term investments.
Management also raised its 2026 outlook. The company now guides total revenue to $582 million–$592 million and testing revenue to $570 million–$580 million, and expects adjusted EBITDA margin to exceed 26%, reflecting confidence in growth from its cancer diagnostic tests and upcoming product launches.
Vanguard Capital Management reports beneficial ownership of 4,132,224 shares of Veracyte Inc, representing 5.20% of the class as of 03/31/2026. The filing shows Vanguard has sole power to dispose of 4,132,224 shares and sole voting power over 599,992 shares. The disclosure attributes ownership to Vanguard Capital Management and affiliated Vanguard entities; signature dated 04/30/2026.
Veracyte Inc reported beneficial ownership by Vanguard Portfolio Management LLC. Vanguard Portfolio Management beneficially owns 4,512,852 shares of Veracyte common stock, representing 5.67% of the class. The filing shows 68,122 shares with sole voting power and 4,512,852 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Veracyte, Inc. is asking stockholders to vote at a virtual Annual Meeting on June 10, 2026. They will elect nine directors for one-year terms, ratify Ernst & Young LLP as auditor, hold an advisory vote on executive pay, and vote on expanding the 2023 Equity Incentive Plan.
The equity plan amendment would add 3,500,000 shares to the plan, on top of 9,704,039 shares available as of March 31, 2026, supporting continued stock-based compensation. The board is majority independent with an independent chair, fully independent committees, majority voting for uncontested elections, clawback policies, and extensive ESG and risk-oversight practices.
Haas Kevin Richard reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. Chief Dev and Tech Officer Kevin Richard Haas received a grant of 44,221 shares of Common Stock on April 10, 2026 as equity compensation. These are restricted stock units awarded at no cash cost to him.
The RSUs vest 25% on June 2, 2027, with the remaining portion vesting in equal 1/16 increments each quarter thereafter, subject to his continued employment on each vesting date. After this grant, he holds 44,221 shares directly according to the filing.
Veracyte Inc. ownership filing: The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0 shares beneficially owned and 0% of common stock following an internal realignment.
The filing states certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Vanguard's Head of Global Fund Administration on 03/27/2026.
VERACYTE, INC. filed an initial insider ownership report for Kevin Richard Haas, who serves as Chief Development and Technology Officer. This Form 3 establishes his status as a reporting officer under SEC rules. The filing does not list any buy, sell, or other share transactions, focusing instead on his reporting obligation as a company insider.
Veracyte, Inc. appointed Dr. Kevin Haas, 40, as Chief Development and Technology Officer, effective March 24, 2026. He previously served as Chief Technology Officer and in senior technology and bioinformatics roles at Myriad Genetics and its women’s health business.
Under his offer letter dated March 13, 2026, Dr. Haas will receive an initial annual base salary of $500,000 and will be eligible for an annual performance-based cash bonus targeted at 55% of eligible annual earnings, with his 2026 bonus prorated based on his start date.
He is also slated to receive a restricted stock unit award with a target value of $1,500,000 vesting over four years and a performance-based restricted stock unit award with a target value of $1,500,000, subject to performance objectives and continued service, all under Veracyte’s 2023 Equity Incentive Plan.